|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...1415161718192021222324...4950» |
- Trial completion, Enrollment change: HIV-1 Specific Immune Responses in Thai Individuals With HIV Dementia (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=60, Completed, Sponsor: South East Asia Research Collaboration with Hawaii
Recruiting --> Completed | N=49 --> 60
- Trial completion, Trial primary completion date: Establishing Normal Values for Neuropsychological Testing in HIV-negative Thais (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=494, Completed, Sponsor: South East Asia Research Collaboration with Hawaii
Recruiting --> Completed | N=49 --> 60 Recruiting --> Completed | Trial primary completion date: Jul 2012 --> Dec 2013
- Trial completion, Trial primary completion date: VICAR2: Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=166, Completed, Sponsor: University of Witwatersrand, South Africa
Recruiting --> Completed | Trial primary completion date: Jul 2012 --> Dec 2013 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Aug 2014
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: LIPOKAL: Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (clinicaltrials.gov) - Sep 19, 2014
P4, N=20, Completed, Sponsor: Juan A. Arnaiz
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Aug 2014 Active, not recruiting --> Completed
- | Trial completion: Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic (clinicaltrials.gov) - Sep 19, 2014
P3, N=1010, Completed, Sponsor: The Miriam Hospital
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial primary completion date, Compliance: Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera (clinicaltrials.gov) - Sep 16, 2014
P=N/A, N=40, Recruiting, Sponsor: Prema Menezes, PhD, PA-C
Enrolling by invitation --> Completed Trial primary completion date: Nov 2014 --> Sep 2015
- ||||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Sep 16, 2014
P3, N=707, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Nov 2014 --> Sep 2015 Active, not recruiting --> Completed
- | Aptivus (tipranavir) / Boehringer Ingelheim
New P2 trial, Combination therapy: Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients (clinicaltrials.gov) - Sep 15, 2014
P2, N=79, Terminated, Sponsor: Boehringer Ingelheim
- | Aptivus (tipranavir) / Boehringer Ingelheim
New P2 trial, Combination therapy: Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients (clinicaltrials.gov) - Sep 12, 2014
P2, N=41, Completed, Sponsor: Boehringer Ingelheim
- efavirenz / Generic mfg.
Trial completion, Enrollment change: Sustiva Levels With Use of a Gel Capsule (clinicaltrials.gov) - Sep 12, 2014
P4, N=16, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=10 --> 16
- | Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Trial completion, Trial primary completion date, Immunomodulating: EraMune02: Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir (clinicaltrials.gov) - Sep 12, 2014
P2, N=28, Completed, Sponsor: Robert L. Murphy
Active, not recruiting --> Completed | N=10 --> 16 Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> Jul 2013
- |||| efavirenz / Generic mfg.
Trial completion: Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805) (clinicaltrials.gov) - Sep 11, 2014
P4, N=90, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> Jul 2013 Active, not recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
Trial suspension: First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers (clinicaltrials.gov) - Sep 10, 2014
P1, N=21, Suspended, Sponsor: Fundacio Lluita Contra la SIDA
Active, not recruiting --> Completed Recruiting --> Suspended
- | rosuvastatin / Generic mfg.
New P4 trial: The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients (clinicaltrials.gov) - Sep 9, 2014
P4, N=82, Not yet recruiting, Sponsor: University of Ottawa Heart Institute
- cyclophosphamide / Generic mfg.
Enrollment change, Trial termination, Combination therapy: Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients (clinicaltrials.gov) - Sep 8, 2014
P1, N=2, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Suspended N=21 --> 2 | Recruiting --> Terminated; Study Funding Terminated
- Enrollment closed, Trial primary completion date: Tissue Drug Levels of HIV Medications (clinicaltrials.gov) - Sep 8, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
N=21 --> 2 | Recruiting --> Terminated; Study Funding Terminated Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Sep 2014
- |||| Isentress (raltegravir) / Merck (MSD)
Trial completion: RADAR: Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients (clinicaltrials.gov) - Sep 8, 2014
P4, N=85, Completed, Sponsor: Dallas VA Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Sep 2014 Active, not recruiting --> Completed
- Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial primary completion date: Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults (clinicaltrials.gov) - Sep 5, 2014
P2, N=360, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2015
- ||||| New P2 trial: Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure (clinicaltrials.gov) - Sep 5, 2014
P2, N=72, Completed, Sponsor: Boehringer Ingelheim
- Enrollment closed: MACS: Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=600, Active, not recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Sep 2014 --> Sep 2015 Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: Problems With Immune Recovery in the Gut Tissue (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=21, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jan 2013
- Aptivus (tipranavir) / Boehringer Ingelheim
New P1/2 trial: Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV (clinicaltrials.gov) - Sep 4, 2014
P1/2, N=3, Terminated, Sponsor: Boehringer Ingelheim
- Enrollment open, Trial initiation date, Trial primary completion date: INTESTIPAX: IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=45, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jan 2013 Not yet recruiting --> Recruiting | Initiation date: Oct 2013 --> Jun 2014 | Trial primary completion date: Oct 2015 --> Jul 2016
- Enrollment open, Trial initiation date, Trial primary completion date: Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread? (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=20, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Recruiting | Initiation date: Oct 2013 --> Jun 2014 | Trial primary completion date: Oct 2015 --> Jul 2016 Not yet recruiting --> Recruiting | Initiation date: Sep 2013 --> Dec 2013 | Trial primary completion date: Sep 2015 --> Mar 2015
- Trial completion, Trial primary completion date: Microparticles, Vector of Genetic Information During HIV Infection (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=15, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Not yet recruiting --> Recruiting | Initiation date: Sep 2013 --> Dec 2013 | Trial primary completion date: Sep 2015 --> Mar 2015 Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Mar 2012
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial initiation date: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Aug 27, 2014
P1, N=72, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Mar 2012 Initiation date: May 2014 --> Aug 2014
- Trial completion, Phase classification, Enrollment change: Transitions: Linkages From Jail To Community (clinicaltrials.gov) - Aug 27, 2014
P=N/A, N=127, Completed, Sponsor: Yale University
Initiation date: May 2014 --> Aug 2014 Recruiting --> Completed | Phase classification: P2 --> PN/A | N=65 --> 127
- Vocabria (cabotegravir oral) / ViiV Healthcare
Enrollment open: Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects (clinicaltrials.gov) - Aug 25, 2014
P1, N=24, Recruiting, Sponsor: ViiV Healthcare
Recruiting --> Completed | Phase classification: P2 --> PN/A | N=65 --> 127 Not yet recruiting --> Recruiting
- | Enrollment open, Trial initiation date, Trial primary completion date: Lactoferrin Treatment in HIV Patients (clinicaltrials.gov) - Aug 25, 2014
P2, N=50, Recruiting, Sponsor: Jason Baker
Not yet recruiting --> Recruiting Suspended --> Recruiting | Initiation date: May 2014 --> Aug 2014 | Trial primary completion date: Jun 2015 --> Mar 2016
- Trial completion, Trial completion date, HEOR: Evaluation of Atazanavir Substitution Intervention (EASI) Study (clinicaltrials.gov) - Aug 22, 2014
P4, N=100, Completed, Sponsor: University of British Columbia
Suspended --> Recruiting | Initiation date: May 2014 --> Aug 2014 | Trial primary completion date: Jun 2015 --> Mar 2016 Active, not recruiting --> Completed | Trial completion date: Sep 2012 --> Sep 2007
- ribavirin / Generic mfg.
New P4 trial: Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study (clinicaltrials.gov) - Aug 21, 2014
P4, N=10, Recruiting, Sponsor: Saint Michael's Medical Center
- Trial completion, Enrollment change, Trial primary completion date: HIV-HCV Coinfection: Impact of Immune Dysfunction (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=634, Completed, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed | Trial completion date: Sep 2012 --> Sep 2007 Recruiting --> Completed | N=800 --> 634 | Trial primary completion date: Sep 2018 --> Aug 2014
- |||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: ARKS: Anti-Retrovirals for Kaposi's Sarcoma (clinicaltrials.gov) - Aug 21, 2014
P4, N=224, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed | N=800 --> 634 | Trial primary completion date: Sep 2018 --> Aug 2014 Active, not recruiting --> Completed
- Trial primary completion date: Intervention for (Those) Recently Informed of Seropositive Status (IRISS) (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Trial primary completion date: Apr 2014 --> Dec 2014
- bortezomib / Generic mfg.
Trial suspension: Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=24, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2014 --> Dec 2014 Recruiting --> Suspended
- | Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
New P4 trial, IO biomarker: Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults (clinicaltrials.gov) - Aug 19, 2014
P4, N=20, Not yet recruiting, Sponsor: University of North Carolina, Chapel Hill
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers (clinicaltrials.gov) - Aug 19, 2014
P1, N=15, Active, not recruiting, Sponsor: ViiV Healthcare
Recruiting --> Suspended Recruiting --> Active, not recruiting
- Enrollment closed: Healthy Options: Group Psychotherapy for HIV-positive Depressed Perinatal Women. (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=720, Active, not recruiting, Sponsor: Harvard Medical School
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- Enrollment closed: A Randomized Controlled Trial of the Bruthas Project (clinicaltrials.gov) - Aug 19, 2014
P2, N=400, Active, not recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial primary completion date, HEOR, Cost effectiveness: Validation of a Simple and Cost-Effective Nucleic Acid Test for HIV Detection (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=100, Recruiting, Sponsor: George Washington University
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2014 --> Apr 2015
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment change, Monotherapy: Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371) (clinicaltrials.gov) - Aug 15, 2014
P3, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Apr 2014 --> Apr 2015 N=448 --> 0
- Trial completion: Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=92, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=448 --> 0 Active, not recruiting --> Completed
- carboplatin / Generic mfg., pemetrexed / Generic mfg.
Trial primary completion date, Metastases: CHIVA: Chemotherapy for Lung Cancer in HIV-positive Patients (clinicaltrials.gov) - Aug 12, 2014
P2, N=62, Recruiting, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Jan 2016
- Phase classification, Trial primary completion date: ART and HCV: Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV (clinicaltrials.gov) - Aug 12, 2014
P1, N=18, Completed, Sponsor: University of Cincinnati
Trial primary completion date: Dec 2013 --> Jan 2016 Phase classification: P2 --> P1 | Trial primary completion date: Aug 2011 --> Mar 2012
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P2 trial: Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents (clinicaltrials.gov) - Aug 11, 2014
P2, N=150, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- ||| Vocabria (cabotegravir oral) / ViiV Healthcare
Enrollment closed: Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR) (clinicaltrials.gov) - Aug 11, 2014
P2a, N=120, Active, not recruiting, Sponsor: ViiV Healthcare
Phase classification: P2 --> P1 | Trial primary completion date: Aug 2011 --> Mar 2012 Recruiting --> Active, not recruiting
- Trial completion: A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers (clinicaltrials.gov) - Aug 11, 2014
P2, N=200, Completed, Sponsor: Barbara Ensoli, MD
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| efavirenz / Generic mfg.
Clinical: Suicidality and Suicide Attempt Among HIV Patients on Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens (clinicaltrials.gov) - Aug 8, 2014
P=N/A, N=8000, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- | Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial, Adherence: dPEP: The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis (clinicaltrials.gov) - Aug 7, 2014
P4, N=100, Recruiting, Sponsor: Andrew Carr
- Enrollment closed, Trial primary completion date, Combination therapy: Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA) (clinicaltrials.gov) - Aug 7, 2014
P4, N=559, Active, not recruiting, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2012 --> Dec 2014